Isoform Oncology is developing new antibody therapies for cancer patients with limited treatment options, particularly where resistance to existing treatments has developed.

The company focuses on targeting cancer-specific protein isoforms that have been largely unexplored, with its lead programme aimed at triple negative breast cancer and bladder cancer.